Heparin is comprised of a linear polysaccharide chain, which is highly negatively charged and found primarily in the granules of mast cells (1). It is the most widely used anticoagulant for cardiac disorders. It is widely used in extracorporeal procedures such as kidney dialysis and heart bypass surgeries (2). Systemic heparinization is also used for treating deep vein thrombosis and in a variety of other surgical procedures (3). A wide variety of biological activities such as antithrombotic, antiatherosclerotic, effect on smooth muscle proliferation, anti-inflammatory, angiogenic and anti-angiogenic activities of heparin and heparin-derived oligosaccharides (4) have resulted in the wide usage of heparin for different pathological conditions. Low molecular weight heparins (LMWHs) are obtained by partial chemical or enzymatic depolymerization of unfractionated heparin. Advantages such as minimal protein binding, reduced incidence of thrombocytopenia, increased bioavailability, and less laboratory monitoring of LMWHs over unfractionated heparin (UFH) make them more amenable for the treatment of thrombotic disorders (5). More than 33 metric tons of heparin are manufactured worldwide each year, representing more than 500 million doses to treat different cardiac disorders (6). The extensive usage of heparin and its derivatives such as LMWHs resulted in the exploration and development of the heparin analogues from different sources (7). The 52 Summary: Biosynthetic, semisynthetic, and synthetic analogues of heparins are currently developed as substitute antithrombotic agents for heparin. Sulfaminoheparosan (SAH) represents a bacterial polysaccharide (K5)-derived antithrombotic polymer from which pharmacologically active products with varying molecular weights (5-25 kDa) can be derived. These agents have been shown to exhibit pharmacologic effects comparable to heparins. The objective of this investigation is to determine the relative neutralization profile of various SAH derivatives, also called as bioheparins, by protamine sulfate. Four SAH fractions with varying molecular weights (20, 9, 7 , and 6 kDa), a low molecular weight heparin (LMWH), tinzaparin, and unfractionated heparin (UFH) were supplemented to normal human pool plasma over a concentration range of 6.2 to 100 µg/mL. A fixed amount of protamine sulfate at 25 µg/mL (final concentration) was supplemented to determine the neutralization profile by performing tests such as prothrombin time (PT), activated partial thromboplastin time (APTT), Heptest, prothrombin-induced clotting time (PiCT), and amidolytic anti-Xa and anti-IIa assays. Protamine sulfate produced varying degrees of neutralization of all bioheparin fractions in the clotting assays. In the amidolytic anti-IIa assay relatively stronger inhibition was noted for all agents than inhibition of FXa. On a cumulative basis the neutralization profile of SAHs was comparable with heparins. These results suggest that the anticoagulant activities of SAH derivatives can be antagonized by protamine sulfate. These studies warrant further in vivo investigation to validate the relative neutralization profile of sulfaminoheparosans.
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The objective of this study was to determine the comparative neutralization profile of these K5 derivatives and heparins by protamine sulfate.
MATERIALS AND METHODS

Materials
Four different K5 derivative fractions (Bio-20 kDa, Bio-9 kDa, Bio-7 kDa, and Bio-6 kDa) with different molecular weights were used in this study. The materials were obtained in the form of a white powder and stored at room temperature. The fractions were provided by Inalco, Milan Italy. Unfractionated heparin (Lot no. RB 21055, Sanofi, Choay Institute, Paris, France) and tinzaparin (Leo Pharmaceutical, Copenhagen, Denmark) were also used in this study for comparative purposes. Both UFH and tinzaparin were also obtained as white powders and were stored at room temperature. Protamine sulfate (Lot no. 87.1143) was obtained from (with approximate mean molecular weight of 4000 Da; Choay, Paris) as a white powder and stored at room temperature.
Methods
The agents were reconstituted in saline at a concentration of 1 mg/mL. The agents were then serially diluted in normal human plasma (NHP) to achieve concentrations of 100 to 6.5 µg/mL. Protamine sulfate was prepared at a concentration of 250 µg/mL in saline. A total of 900 µL of each sample was mixed with 100 µL of protamine sulfate at 250 µg/mL so that the final con-centration of protamine sulfate was 25 µg/mL. A total of 900 µL of each test agent mixed with 100 µL of saline was used as control. The following anticoagulant tests and amidolytic chromogenic assays were performed on the test samples supplemented with protamine sulfate and saline control groups.
i. Prothrombin time (PT)
This assay was performed by using ACL 300 Plus fast kinetic coagulation analyzer. Thromboplastin-C (Dade, Miami, FL) was reconstituted with 10 mL of distilled water before the test was performed and placed in the designated position. The test was performed according to the parameters set on the instrument and the clotting times were measured.
ii. Activated partial thrombin time (APTT)
This assay was performed by using ACL 300 Plus fast kinetic coagulation analyzer. The APTT reagent (Organon Teknika, Morris Plains, NJ) was reconstituted with 6 mL of distilled water before the test was performed. The APTT reagent and calcium chloride (0.025 M from Organon Teknika) were placed in designated positions. The test was performed according to the manufacturer's specifications and the clotting times were measured.
iii. Heptest
In this assay, the bovine factor Xa and Recalmix (Haemochem, St. Louis, MO) were reconstituted with 2 mL of distilled water before the test was performed; 100 µL of each of these plasma samples and 100 µL of bovine factor Xa were incubated for 2 minutes at 37°C. Clotting time was measured by using Fibrometer, after the addition of 100 µL of prewarmed Recalmix. Measurement of clotting time was stopped at 300 seconds, as clotting times beyond 300 seconds were outside of the linear range of the instrument.
iv. Prothrombin-induced clotting time (PICT)
The assay was performed on the ACL 300 Plus fast kinetic coagulation analyzer. In this assay, Reagent 1 (R1 from Pentapharm LTD, Basel, Switzerland) was reconstituted with 2 mL of deionized water and incubated for 15 minutes at room temperature and swirled gently before use; 500 µL of each of these sample plasmas was placed into individual test cups, which were then placed in an ACL test cup carousel in a defined sequence. Normal human plasma was included in every carousel as a control. The reagents were placed in their appropriate positions (reagent 1 in position 2 and reagent 2, 25 mM CaCl 2 , in position 3). The test results were noted as seconds.
v. Anti-Xa assay
The assay was performed on the ACL 300 Plus fast kinetic coagulation analyzer. In this assay, Spectrozyme FXa (5 µmol from American Diagnostica, Greenwich CT) was reconstituted with 2 mL of distilled water and bovine factor Xa (0.02 mg from Enzyme Research Laboratories, South Bend, IN) was reconstituted with 3 mL of Xa/IIa buffer (50 mM Tris-HCl, 7.5 mM EDTA, and 0.15 M NaCl, pH 8.4) before use; 250 µL of each of these sample plasmas was placed into individual test cups, which were then placed in an ACL test cup carousel in a defined sequence. Normal human plasma and saline samples were included in every carousel as controls. The reagents were placed in their appropriate positions (bovine factor Xa in position 2 and Spectrozyme FXa in position 3); 10 µL of plasma was incubated for 1 minute at 37°C, followed by an addition of 100 µL of bovine factor Xa. After 5 minutes of incubation at 37°C, 75 µL of Spectrozyme FXa was added and the change in optical density (OD) at 405 nm was measured for 30 seconds. The optical density values were then converted to percent factor Xa inhibition in relation to baseline (OD value of NHP) by using the following formula:
vi. Anti-IIa assay
The assay was performed on the ACL 300 Plus fast kinetic coagulation analyzer. In this assay, 250 µL of each of these sample plasmas was placed into individual test cups, which were then placed in an ACL test cup carousel in defined sequence. Normal human plasma and saline samples were included in every carousel as controls. The reagent, Spectrozyme TH (5 µmol from American Diagnostica) was reconstituted with 5 mL of distilled water and human α-thrombin (Enzyme Research Laboratories) was diluted to 10 U/mL. The reagents were placed in their appropriate positions (thrombin in position 2 and Spectrozyme TH in position 3); 10 µL of plasma was incubated for 1 minute at 37°C, followed by an addition of 100 µL of thrombin. After 1 minute of incubation at 37°C, 40 µL of Spectrozyme TH was added and the change in optical density (OD) at 405 nm was measured for 30 seconds. The optical density values were then converted to percent factor II inhibition in relation to baseline (OD value of NHP) using the formula mentioned above. The anticoagulant and antiprotease effects of these agents were determined in triplicate.
The results obtained from both the saline control groups and the protamine sulfate neutralized groups were compared and percent neutralization of each agent in each assay was calculated. The anticoagulant agent was considered as partially neutralized when the percent decrease in anticoagulant or antiprotease activity is 40 to 50, relatively "more neutralized" was used when the percent decrease in the effect is 50 to 70, and "neutralized to the maximum" was used when the percent decrease in the effect is 70 to 90. The agents were considered as "completely neutralized" when the percent decrease in their effects is 90 to 100.
Statistical Analysis
The data represented mean ± standard deviation values of three individual experiments. Paired t test was performed to determine the statistical significance (P < .05).
RESULTS
At a concentration of 25 µg/mL the prothrombin time was prolonged in a concentration-dependent manner by bioheparin fractions, UFH, and tinzaparin ( Fig. 1A ). When neutralized with protamine sulfate, the clotting times were decreased to baseline values, which was 11 seconds (Fig. 1B) at equigravimetric concentration (the concentration of test agents is equal to the concentration of protamine sulfate, ie, 25 µg/mL).
The APTT was prolonged up to 300 seconds for all the compounds except for bio-6 kDa at the concentration of 25 µg/mL ( Fig. 2A) . The bioheparin fractions, bio-20 kDa, and bio-9 kDa, and UFH exhibited partial neutralization with protamine sulfate whereas the bio-7 kDa, bio-6 kDa, and tinzaparin exhibited complete neutralization at the equigravimetric concentration. However, at the concentration of 12.5 µg/mL all the compounds were neutralized to the maximum (Fig. 2B) .
The saline controls of all the bioheparin fractions, UFH, and tinzaparin exhibited maximum anticoagulant effects in the Heptest at 25 µg/mL ( Fig. 3A) . When neutralized with protamine sulfate, the clotting times were decreased for only bio-7 kDa, bio-6 kDa, and tinzaparin. Bio-20 kDa, bio-9 kDa, and UFH exhibited maximal effects (with clotting times 50-60 seconds less than the clotting times of saline controls) even after neutralized with protamine sulfate at an equigravimetric concentration. However, at a concentration of 12.5 µg/mL, all the bioheparin fractions, UFH, and tinzaparin were neutralized to the maximum, with the clotting times decreased to 50 to 70 seconds (Fig. 3B) .
The prolongation of clotting times in the PICT assay by bioheparin fractions followed a clear molecular weight dependency (Fig. 4A ). Interestingly, despite its low molecular weight, tinzaparin was more effective than bio-9 kDa, bio-7 kDa, and bio-6 kDa at 25 µg/mL. With the protamine sulfate neutralization at an equigravimetric concentration, all bioheparin fractions and tinzaparin were completely neutralized, with clotting times decreased to 50 to 60 seconds from saline control values (Fig. 4B) . UFH was only partially neutralized, with clotting times 140 seconds at equigravimetric levels. However, at 12.5 µg/mL UFH was neutralized to the maximum (clotting time = 30 seconds) by protamine sulfate.
The neutralization pattern of the antiprotease effects of bioheparin fractions, UFH, and tinzaparin followed a similar neutralization pattern to the anticoagulant effects.
The inhibition of factor IIa by bioheparin fractions 20 kDa, 9 kDa, 7 kDa, and 6 kDa followed a clear molecular weight dependency (Fig. 5A) . Protamine sulfate did not appear to be an effective neutralizing agent for bioheparin fractions 20 kDa, 9 kDa, 7 kDa, and UFH at an equigravimetric concentration where the concentration of protamine sulfate versus test agent was equal to 1:1. However bio-6 kDa and tinzaparin were completely neutralized at the same concentration level. Interestingly, at 12.5 µg/mL all the compounds were completely neutralized by protamine sulfate except for bio-20 kDa, which was only partially neutralized ( Fig. 5B ). As shown in Fig. 6 , there was a significant reduction (P < .005, paired t test) in the potencies (in terms of increased IC 50 values of FIIa inhibition) of all the bioheparin fractions, UFH, and tinzaparin when saline controls were compared to the protamine sulfate neutralized groups.
The bioheparin fractions, UFH, and tinzaparin exhibited maximum inhibition (85-95%) of factor-Xa in a chromogenic anti-Xa assay (Fig. 7A ) at a concentration of 25 µg/mL. Protamine sulfate (25 µg/mL) was able to neutralize these compounds minimally (residual 75-85% of FXa inhibition) at an equigravimetric concentration. However, at 12.5 µg/mL of test agents, protamine sulfate was able to partially neutralize bio-20 kDa, bio-9 kDa, and UFH. Bio-7 kDa and bio-6 kDa were neutralized more than 50% (62-65%) (Fig.  7B) . Tinzaparin was the least neutralized of all the compounds at 12.5 µg/mL. As depicted in Fig.  8 , the potency values (in terms of IC 75 values of FXa inhibition) of all the bioheparin fractions, UFH, and tinzaparin significantly reduced (P < .005, paired t test) when saline controls were compared with protamine sulfate groups.
DISCUSSION
Protamine sulfate is commonly used to neutralize the anticoagulant and bleeding affects of unfractionated heparin (18) (19) (20) . Protamine sulfate is capable of neutralizing heparin by complexing with heparin, thereby impairing its ability to interact with antithrombin (AT) and heparin cofactor II (HC-II). Furthermore, upon protamine sulfate complexation, heparins and related agents are unable to release tissue factor pathway inhibitor (TFPI). Protamine sulfate is capable of neutralizing unfractionated heparin in a gravimetric ratio of 1:1. However, the molecular weight of protamine sulfate is much lower than that of heparin. For this reason the neutralization profile of low molecular weight heparin is different in comparison to unfractionated heparin (21, 22) . Furthermore, the biologic half-life of protamine sulfate is shorter than that of both UFH and LMWHs. Regardless of these limitations, protamine sulfate represents the only pharmacological antagonist of UFH and LMWHs (23) .
Sulfaminoheparosans are structurally similar to heparin having a similar chemical composition of their predominant disaccharide units. Fig. 9 compares a representative structure of a heparin disaccharide unit and a sulfaminoheparosan disaccharide unit. As both agents contain sulfate groups, protamine sulfate is capable of complexing with both the bioheparins and heparins. It was projected that protamine sulfate may be capable of neutralizing the anticoagulant effects of sulfaminoheparosans. Thus, the current studies were undertaken to compare the neutralization profile of heparins (UFH and tinzaparin) and several of the bioheparin fractions (Bio-20, 9, 7, and 6 kDa). Several clot-based methods were used including PT, APTT, Heptest, a newly developed prothrombin-induced clotting time test (PICT), and amidolytic anti-Xa and anti-IIa methods. The test system included normal human pool plasma supplemented at varying concentrations of each of these agents in a concentration range of 0 to 100 µg/mL. Protamine sulfate was used at fixed concentration of 25 µg/mL.
The neutralization profile of both the heparins and the sulfaminoheparosans was assay dependent and varying degrees of neutralization were observed in each of the individual assays. In the PT assay the relative anticoagulant effects of bio-20 kDa and UFH were stronger where as the bio-9, 7, and 6 kDa, and tinzaparin produced weaker effects. Protamine sulfate (25 µg/mL) produced an almost complete neutralization of the anticoagulant effects of bio-20 kDa (93%) at 12.5 µg/mL. However, the percent neutralization of bio-9 kDa, bio-7 kDa, and UFH was less than the bio-20 kDa at the same concentration. Bio-6 kDa and tinzaparin were least neutralized. In the APTT assay, heparins and bioheparins produced relatively stronger anticoagulant effects in comparison to the PT assay. Both UFH and bio-20 kDa exhibited stronger anticoagulant effects. Interestingly, the relative percent neutralization of bio-20 kDa (43%) was weaker in comparison with the percent neutralization in the PT assay at the same concentration. Thus, a differential neutralization profile can be observed in the extrinsic (PT) and the intrinsic (APTT) assay systems. In the Heptest assay where a clot-based anti-Xa/IIa method is used, bio-20 kDa and bio-9 kDa showed less than 25% neutralization and UFH was minimally neutralized at a 1:1 ratio of protamine sulfate to the agent. Tinzaparin, bio-7 kDa, and bio-6 kDa were more than 50% neutralized. However, at a 2:1 ratio of protamine sulfate to the agent, all the agents were neutralized to more than 60%. In the PICT test at equigravimetric amounts, all of the agents were effectively neutralized and exhibited more than 50% neutralization and at a 2:1 ratio of protamine sulfate to the agent more than 80% of neutralization of all the agents was noted. This suggests that since different clot-based assays measured the coagulation process at different stages, the relative neutralization profile of bioheparins and heparins is both product and assay dependent, which may be related to the structural composition of these agents.
There was a relationship between the molecular weight and the neutralization profile of these agents by protamine sulfate. However, this relevance was assay dependent due to the variation in the test specificity of different assays. For example, PT did not show any molecular weight dependence in the neutralization profile, but there was a molecular weight dependence noted in the APTT assay. Similarly in the Heptest, anti-IIa, and anti-Xa assays, a molecular weight dependence was observed.
Amidolytic assays such as anti-IIa and anti-Xa are commonly used to study the pharmacokinetics of heparins. These assays measure the inter-action of heparins and bioheparins with AT and HC-II. While the AT interactions with bioheparins resulting in the inhibition of thrombin and FXa were found to be comparable to heparins, the relative inhibition of thrombin by bioheparins upon their interaction with HC-II was very strong (24) . The bioheparin fractions and heparins exhibited differences in the amidolytic antiprotease activities, which could be due to the compositional variations of these agents. In the amidolytic anti-IIa assay, at a 1:1 ratio, protamine sulfate effectively neutralized bio-6 kDa and tinzaparin in comparison to the other agents. All the agents were neutralized to more than 95% except bio-20 kDa (53%) at a 2:1 ratio of protamine sulfate to the agent. However, the neutralization profile of anti-Xa activity was quite weak for all the agents at the same proportion of protamine sulfate to bioheparin fractions or heparins.
The amidolytic anti-IIa and Xa methods provide an opportunity to quantitate the relative neutralization by protamine sulfate. The IC 50 values for the inhibition of thrombin were less than 10 µg/mL for all the agents in the control groups. However the IC 50 values were significantly (P< .05) increased in a molecular weight-dependent fashion for the bioheparins. The IC 50 values were inversely proportional to the molecular weights. Both UFH and tinzaparin were also effectively neutralized for their anti-IIa activities. The relative neutralization of the anti-Xa effects required different amounts of bioheparins and heparins. The relative potencies to inhibit factor Xa were significantly (P < .05) increased from control groups to protamine sulfate neutralized groups of both the bioheparins and the heparins.
To compare the composite neutralization profile of various bioheparins in different assays at a concentration of 12.5 µg/mL, an averaged neutralization index was computed by taking a mean of the neutralization of each of the agents in different assay systems ( Table 1 ). All four bioheparin fractions were neutralized to 73% to 76%. UFH was most affected by the protamine sulfate with percent neutralization of 84 and tinzaparin was the least affected of all the agents by protamine sulfate with percent neutralization of only 66. The averaged data as shown in the table does not suggest any molecular weight dependence on neutralization. However, it demonstrates that the relative neutralization is dependent on their structural composition. Thus, the relative antagonism of these agents by protamine sulfate is product dependent. For those agents partially neutralized by protamine sulfate, it is likely that a stronger dosage may be required to neutralize their effects. The relevance of a protamine sulfate neutralization profile of each agent as stated in terms of averaged index to pharmacodynamic responses such as bleeding is not clear. There are no experimental or clinical data available on the potential bleeding effects of these agents at this time. To validate the protamine sulfate neutralization indices as predictive parameters for bleeding potential, in vivo studies in animal models are warranted. The degree of anticoagulation during surgical interventions varies widely. Protamine sulfate can be used to optimize the relative anticoagulation state. The dose of the protamine sulfate can be adjusted to achieve partial or total neutralization of the anticoagulant drug. It can be noted from the dose-response results of the bioheparins that the degree of the anticoagulant effects of these agents can be adjusted to a desirable level. This is commonly practiced when heparin rebound is observed.
Protamine sulfate is the only heparin antagonist used clinically at this time. Since sulfaminoheparosan-derived agents structurally mimic heparin, this pharmacological antagonist of heparin may be effective in the neutralization of the anticoagulant and bleeding actions of these heparin-like compounds. However, for the proper development of new anticoagulants, the availability of a clinically useful and approved antagonist is very helpful. The studies reported in this communication indicate that protamine sulfate may be useful in the management of any potential bleeding and undesirable anticoagulant effects of bioheparins. Protamine sulfate can be considered for the neutralization of these agents in future clinical trials. Tinzaparin 66 *Cumulative percent neutralization of bioheparin fractions and heparins, computed by averaging the relative neutralization at 12.5 µg/mL of each of the agents in different assay systems. All the four bioheparin fractions were neutralized to 73-76%. UFH was most affected by the protamine sulfate with percent neutralization of 84, and tinzaparin was the least affected of all the agents by protamine sulfate with percent neutralization of only 66.
